Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen

Chemical Research in Toxicology

Volumn 10, Issue 2, 1997, Pages 189-196

  Dasaradhi, Lakkaraju ^a   Shibutani, Shinya ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TAMOXIFEN DERIVATIVE;

ARTICLE; DNA ADDUCT; DNA DETERMINATION; DRUG DETERMINATION; DRUG DNA BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE;

DEOXYGUANOSINE; DNA; DNA ADDUCTS; TAMOXIFEN;

EID: 0031054835     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960114h     Document Type: Article

References (33)

1. Jordan, V. C. (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110, 507-517.
2. Powles, T. J., Hardy, J. R., Ashley, S. E., Farrington, G. H., Cosgrove, D., Davey, J. R., Dowsett, M., McKinna, J. A., Wash, A. G., Sennet, H. D., Tillyer, C. R., and Treleaven, J. G. (1993) A pilot trial to evaluate the acute toxicology and feasability of tamoxifen for the prevention of breast cancer. Br. J. Cancer 60, 126-131.
3. Nayfield, S. G., Karp, J. E., Ford, L. G., Dorr, F. A., and Kramer, B. S. (1991) Potential role of tamoxifen in prevention of breast cancer J. Natl. Cancer Inst. 83, 1450-1459.
4. Seoud, M. A.-F., Johnson, J., and Weed, J. C. (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol. 82, 165-169.
5. Fischer, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., and Cronin, W. M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537.
6. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W. W., Kiemeney, L. A. L. M., Diepenhorst, F. W., van den Belt-Dusebout, A. W., and van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
7. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., and Kaltenberg, O. P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
8. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wister-derived rats. Cancer Res. 53, 3919-3924.
9. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541.
10. Vancutsem, P. M., Lazarus, P., and Williams, G. M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res. 54, 3864-3867.
11. Lawley, P. D. (1994) From fluorescence spectra to mutational spectra, a historical overview of DNA-reactive compounds. In DNA Adducts: Carcinogen & Mutagenic Agents: Chemistry, Identification & Biological Significance (Hemminki, K., et al., Eds.) Publication 125, pp 3-22, IARC Scientific Lyon, France.
12. Pathak, D. N., and Bodell, W. J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15, 529-532.
13. Pathak, D. N., Pongracz, K., and Bodell, W. J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 16, 11-15.
14. Hemminki, K., Widlak, P., and Hou, S. M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocyte in vitro. Carcinogenesis 16, 1661-1664.
15. Han, X., and Liehr, J. G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52, 1360-1363.
16. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
17. Carthew, P., Martin, E. A., White, I. N. H., DeMatteis, F., Edwards, R. E., Dorman, B. M., Heydon, R. T., and Smith, L. L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547.
18. Poon, G. K., Walter, B., Lfnning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and in patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382.
19. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54, 5518-5522.
20. Boberg, E. W., Miller, E. C., Miller, J. A., Poland, A., and Liem, A. (1983) Strong evidence from studies with brachymorphic mice and pentachlorophenol that I'-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of I'-hydroxysafrole in mouse liver. Cancer Res. 43, 5163-5173.
21. Phillips, D. H., Miller, J. A., Miller, E. C., and Adams, B. (1981) Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen I'-hydroxyestragole. Cancer Res. 41, 176-186.
22. Watabe, T., Ishizuka, T., Isobe, M., and Ozawa, N. (1982) A 7-hydroxy-methyl sulfate ester as an active metabolite of 7,12-dimethyl-benz[a]anthracene. Science 215, 403-405.
23. Watabe, T., Hiratsuka, A., Ogura, K., and Endoh, K. (1985) A reactive hydroxymethyl sulfate ester formed regioselectively from the carcinogen, 7,12-dihydromethyl-benz[a]anthracene, by rat liver sulfotransferase. Biochem. Biophys. Res. Commun. 131, 694-699.
24. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087-2094.
25. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
26. Foster, A. B., Jarman, M., Leung, O.-T., McCague, R., Leclercq, G., and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem. 28, 1491-1497.
27. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
28. 32P-postlabeling. Carcinogenesis 12, 1181-1186.
29. 2-AAF and oxidation products of dG-C8-AF. Carcinogenesis 12, 813-818.
30. Potter, G. A., McCague, R., and Jarman, M. (1994) A mechanism hypothesis for DNA adduct formation by tamoxifen hepatic oxidative metabolism. Carcinogenesis 15, 439-442.
31. Moorthy, B., Sriram, P., Pathak, D. N., Bodell, W. J., and Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vitro. Cancer Res. 56, 53-57.
32. Phillips, D. H., Hewer, A., White, I. N. H., and Farmer, P. B. (1994) Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis 15, 793-795.
33. 5-ethyll-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15, 1487-1492.